A

Anavex Life Sciences Corp
D

AVXL

9.08000
USD
0.06
(0.67%)
Market Closed
Volume
46,598
EPS
-1
Div Yield
-
P/E
-18
Market Cap
769,943,294
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    748 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    P
    PBYI
    -0.57500
    (-19.23%)
    2.41500 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SAGE
    -0.26000
    (-4.84%)
    5.11000 USD
    More
News

Title: Anavex Life Sciences Corp

Sector: Healthcare
Industry: Biotechnology
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.